Clinical Significance of Fasting Glucose Criteria in Metabolic Syndrome

ABSTRACT

Both Adult Treatment Panel III(ATP III) and International diabetes Federation(IDF) adopted impaired fasting glucose (IFG) as one of the criteria for identifying individuals with metabolic syndrome. However, many studies have shown that IGT is a better predictor of cardiovascular disease(CVD) than IFG. Recently the American Diabetes Association(ADA) revised the diagnostic criteria for IFG, lowering the diagnostic threshold from 110 mg/dL to 100 mg/dL to improve the alignment of IFG and IGT. Although the revised definition of IFG increases the prevalence of metabolic syndrome as well as that of IFG, relative risk of CVD is still lower than that of IGT. The clinical and public health implications of the revised IFG definition remain to be elucidated.